NanoStics
Edmonton, CA · 2 known investors
Find your way into NanoStics
862 people in our graph share verified history with the NanoStics team — schools, employers, funds. One of them is your warm intro.
Hannes Voucko-Glocknerunlockedknows Catalina Vasquez · together at Massachusetts Institute of Technology (overlapped)
knows the team · via Massachusetts Institute of Technology
×2knows the team · via Dalhousie University
knows the team · via Western University
knows the team · via Institute of Corporate Directors
×4knows the team · via University of Victoria
Nanostics is a precision health company developing non-invasive diagnostic tests and medical devices that use machine learning to detect and assess aggressive cancers such as prostate cancer, aiming to improve diagnosis and healthcare decisions. It serves clinicians and patients in the cancer diagnostics field.
Founders & leadership
JD
John D. LewisinFounder, Board Chair & CEOJohn D. Lewis founded Nanostics, a precision health company developing non-invasive diagnostic tests using machine learning to detect aggressive cancers. His research background spans nanotechnology and imaging technologies applied to chronic diseases including cancer metastasis.
RP
Robert PaproskiinCo-founder & Chief Technology Officer
EH
Eric HyndmanMedical Officer
CV
Catalina VasquezinChief Operating OfficerCatalina Vasquez is Chief Operating Officer of NanoStics, a precision health company developing non-invasive diagnostic tests for aggressive cancers using machine learning.
DP
Desmond PinkinChief Scientific OfficerDesmond Pink has spent over a decade in biotechnology development and translational science, with expertise spanning amino acid biochemistry, tumor biology, intravital imaging, and targeted lipid nanoparticle delivery. He is Co-Founder and Chief Scientific Officer of Nanostics, a University of Alberta spin-off developing liquid biopsy diagnostics that combine clinical biomarkers and machine learning for cancer risk assessment.
CC
Colin CorosinChief Commercialization OfficerColin Coros is Chief Commercialization Officer of NanoStics, a precision health company developing non-invasive diagnostic tests for aggressive cancers. He has background in biotechnology, finance, and business development.
Investors · 2
Competitors · 7
by search overlap
Nanodiagnostics5 shared keywordsNanoDx develops point-of-care diagnostic devices using nanowire biosensor technology to deliver rapid test results at patient locations, targeting unmet clinical needs globally.
Nostics4 shared keywordsNostics develops a portable optical biosensor that measures real-time spectral signals from pathogens in patient samples, using its Spectral Foundation Model to identify infections at the point of care in under 10 minutes. The platform targets healthcare providers seeking rapid, lab-comparable infection diagnostics for decentralized settings and to address antimicrobial resistance.
Nanobiotix4 shared keywordsNanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients. The company builds on French scientific research and targets patients worldwide through disruptive treatment approaches.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
NOWDiagnostics (NOWDx)3 shared keywordsNOWDiagnostics develops rapid, point-of-care and consumer diagnostic tests. The company operates in the medical diagnostics and MedTech industry.
Radionetics3 shared keywordsRadionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands. The company is headquartered in San Diego, California, and focuses on theranostic applications in oncology.
Fortis Life Sciences3 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Companies competing with NanoStics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does NanoStics do?
- Nanostics is a precision health company developing non-invasive diagnostic tests and medical devices that use machine learning to detect and assess aggressive cancers such as prostate cancer, aiming to improve diagnosis and healthcare decisions. It serves clinicians and patients in the cancer diagnostics field.
- Who founded NanoStics?
- NanoStics was founded by John D. Lewis, Robert Paproski.
- Who are NanoStics's investors?
- NanoStics's investors include ScaleGood Fund LP (powered by TELUS), Startup TNT.
- Where is NanoStics headquartered?
- NanoStics is headquartered in Edmonton, CA.